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Challenges and opportunities for antimicrobial stewardship in resource-rich 
and resource-limited countries 
 
Abstract 
Introduction: Inappropriate prescription practices, patient and provider knowledge and 
attitudes, variable availability of diagnostics and surveillance systems, and the unrestricted 
use of antimicrobials in animals and plants are contributory factors to the global crisis of 
antimicrobial resistance (AMR).  
Areas covered: Notwithstanding that interventions to revert AMR should be tailored to the 
socio-politico-economic landscape, there is global consensus for the implementation and 
enhancement of antimicrobial stewardship strategies. Yet the implementation of 
Antimicrobial Stewardship Programs (ASPs) remains relatively limited within healthcare 
settings and faces complex challenges in resource-limited countries. The current review 
summarizes the limitations of current ASPs, translation challenges in resource-limited 
countries, and potential solutions.  
Expert opinion: Suboptimal ASP implementation in hospitals is multifactorial. Restriction of 
antimicrobial use should be informed by risk-benefit analyses, including the potential for 
substitute prescribing, and displacement of selection pressures. Thresholds in population 
use of antibiotics above which AMR increases may provide quantitative targets for ASPs. 
Horizontal and vertical collaborations involving policymakers and the general public are of 
paramount importance. While impactful prescribing changes require sustained engagement 
of the public and healthcare professionals, we warn against over-estimating the benefits of 
behavioral interventions. We advocate for population level stewardship interventions in 
addition to investment in structural factors that will aid ASP implementation. 
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• ASPs remain a critical tool in the reversal of AMR within hospital and community settings.  
• ‘Back-end’ strategies are more widely practiced as persuasive and educational initiatives, 
but ‘front-end’ strategies and restriction may be more effective. 
• Improved diagnostics and surveillance provide opportunities for ensuring empirical and 
prophylactic therapies are appropriate, and for early rationalization or de-escalation. 
• Aggregate prescribing and AMR data can be used to identify the thresholds in population 
use of specific antimicrobials above which clinical burdens from AMR pathogens 
increase. This may provide quantitative targets for ASPs and serve as a practical 
alternative to total restriction of antimicrobials, which is not always feasible or desirable. 
• There is evidence suggesting that the indiscriminate use of biocides increases AMR. 
ASPs should be broadened to include the use of biocides.  
• ASPs should be informed by a ‘One Health’ approach that integrates AMR research 
relating to human and veterinary health as well as agriculture and the environment.  
• A tiered approach, ensuring vertical and horizontal coordination amongst all stakeholders, 
is key to the implementation of ASPs. 
• Economic development is one of the prime determinants of AMR burden and the likely 
capacity to implement ASPs. International cooperation, technology sharing, and greater 
investment in AMR research in low- and middle-income countries is needed to adapt 
ASPs to socio-political, public health and economic challenges, recognizing both the 
importance of improving access and limiting excess.  
• Diffusion of lower cost and point-of-care diagnostics and IT for surveillance, health 
system strengthening, reductions in out-of-pocket healthcare expenditures, and reducing 
burdens of infectious disease or associated risk-factors, provide opportunities for ASPs in 
low- and middle-income countries. 
• Behavioral interventions, such as enablement and restriction in particular, are promising 




Lax prescribing standards and the inappropriate use of antimicrobials around the world have 
contributed to the steady rise of antimicrobial resistance (AMR). It has been confirmed that 
mortality of patients with bacteremia associated with multidrug resistant infections is 
significantly higher compared to bacteremia patients where multidrug resistant bacteria was 
not isolated (40.5% vs. 28.5%, p<0.001) (Sirijatuphat et al., 2018). Should the current AMR 
trend continue, it is estimated that AMR will lead to 10 million deaths every year by 2050, 
posing a massive financial and societal problem (O'Neill, 2014). In 2017, the World Bank 
warned that AMR would exert a drag on global gross domestic product (GDP) from 1.1 to 
3.8% points between then and 2050 (World Bank, 2017). At present, the annual cost of 
treating antibiotic-resistant infections is already estimated to be 21-34 million US dollars 
(Infectious Diseases Society of America [IDSA], 2011). 
 Several interdependent factors spanning across human and animal health, pharmaceuticals, 
food and agriculture, environment, trade and finance contribute to AMR, making it one of the 
most complex public health challenges globally. Meeting this challenge is clearly beyond the 
ability of any single organization or government. Containing and controlling AMR demands 
international coordinated efforts across the range of sectors mentioned above (World Health 
Organization [WHO], 2018). The World Health Organization (WHO) instituted a global action 
plan with the development and implementation of antibiotic stewardship programs (ASP) 
being one of its key components (WHO, 2015). In 2019, WHO has identified AMR as one of 
the top ten global health threats (WHO, 2019). Antimicrobial stewardship continues to play a 
dominant role in current strategies to tackle AMR (i.e. the United Kingdom’s five-year 
National Action Plan, 2019-2024). As an emerging field, ‘antimicrobial stewardship’ is still 
loosely defined as an umbrella of strategies and interventions that seek to measure and 
improve the use of antibiotics to reverse the rising threat of global AMR (Figure 1). The 
structure of ASPs differs depending on healthcare and cultural settings, but the core aims of 
any ASP is to reduce AMR rates, preserve current antibiotics, improve patient outcomes and 
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safety, as well as, to reduce the financial costs posed by inappropriate antibiotic prescription. 
It is important to understand that ASPs are not the elixir to reverse AMR. They should be 
complemented with regulatory policies and educational measures to control antibiotic use in 
humans and livestock, the promotion of research and development (R&D) of new classes of 
safe and effective antimicrobials and non-antimicrobial alternatives, and, last but not least, 
infection-control and improved water, sanitation and hygiene (WASH) conditions. 
 
2. Current antimicrobial stewardship interventions - strengths and limitations 
Successful implementation of ASPs requires the development of targeted strategies to 
achieve feasible and sustainable outcomes. Within hospital settings, the focus should be on 
the reduction and streamlining of use of total or specific antimicrobials, the improvement of 
susceptibility profiles of hospital-borne pathogens, the improvement of clinical markers (such 
as reduced length of stay) and continuous quality management. Regarding quality 
assurance, monitoring for unintended harms, such as increasing rates of adverse drug 
reactions, substitute prescribing, new resistances, worsening clinical outcomes, should be 
implemented. Measures of direct and indirect benefits or harm of ASPs are listed below. 
 
Measures of direct benefit 
a.  Reduction in total antibiotic use (DODs, DDDs, prescriptions per 1000 OBDs or IDs) 
b.  Reduction in use of targeted (high-risk) antibiotics 
c.  Minimization in seasonal fluctuations in total or specific prescribing 
d.  Reduction in sentinel resistant infections (e.g. MRSA, ESBL, multidrug resistant 
Gram-negative bacteria) or improvements in susceptibility profiles 
e.  Reduction in acquisitions of colonization 
 
Measures of indirect benefit or harm 
a. Change in clinical outcomes 
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b. Change in hospital standardized mortality ratios 
c. Change in infection syndrome-specific mortality  
d. Change in length of stay and re-admission 
e. Change in use of non-target antibiotics 
f. Change in adverse drug reactions arising from antibiotic use 
 
These outcomes can be achieved with ‘front–end’ ASP restrictive strategies where 
antimicrobials are made available through formulary restrictions and preauthorization. ‘Back-
end’ persuasive strategies can also be implemented, where antimicrobial use is reviewed 
after antimicrobial therapy has been initiated, e.g. prospective audit with intervention and 
feedback. Back-end strategies are more widely practiced than front-end strategies despite 
them being more labor-intensive, for the following reasons (Chung, Wu, Yeo, Chan & Hsu, 
2013): a) higher feasibility and acceptability to clinicians, b) feedback mechanisms and, thus, 
opportunities for the development of educational and quality enhancement initiatives, c) 
proved sustained impact on improvement of antimicrobial prescribing practices. As further 
discussed in section 5.3, it has been shown that enabling strategies enhance the effect of 
restrictive interventions (Davey et al., 2017). 
 
2.1 Development of scenario-specific clinical guidelines 
Every country should have a National Action Plan (NAP) addressing the stewardship goals 
outlined in the WHO Global Action Plan to combat AMR. Such plans should be informed by 
updated trends in antimicrobial resistance and prevalence of infectious diseases in hospital 
and community settings. NAPs are an opportunity to identify relevant experts and 
incorporate their opinions in the development of local treatment algorithms for all frontline 
healthcare professionals. Multicenter, observational studies have shown that the 
standardization and streamlining of prescribing guidelines has the acknowledged benefit of 
a) reducing unnecessary antimicrobial use b) decreasing length of therapy and c) reducing 
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prescription costs for hospital-acquired infections (Huijts et al., 2013; Pradelli et al., 2015). 
On the contrary, a recent meta-analysis revealed that clinical guidelines have no positive 
effect on resistance rates; perhaps due to short follow-up periods, small sample sizes and 
poor study designs (Baur et al., 2017). Nonetheless, in resource-limited circumstances 
adherence to local guidelines can provide initial success which should be followed by 
resource-demanding core strategies, such as prospective auditing and feedback. The 
sustained adherence to these guidelines over time may be necessary and intended 
outcomes should be closely monitored. 
2.2 Education of prescribers 
Guidelines should reach healthcare providers, relevant professional societies and, where 
appropriate, the general public. Frontline clinicians are educated on antimicrobial prescribing 
as part of the review of treatment algorithms which can occur while obtaining authorization to 
use restricted antimicrobials, during formal review and feedback sessions by antimicrobial 
stewards or through formal didactic sessions. A Cochrane review published in 2013, 
demonstrated that dissemination via printed educational material or meetings was 
associated with improved antibiotic use in 5 of 6 studies; the median effect size based on the 
type of study ranged from 10.6% to 42.5%. However, no comparative studies have been 
conducted to determine which educational strategy is most effective. Ultimately, educational 
strategies are likely most effective when combined with other stewardship strategies such as 
prospective audit and feedback methods (Davey et al., 2017). 
2.3 Formulary restriction and preauthorization 
Formulary restriction works on the principle that only certain antimicrobials are made 
available within hospital settings in order to reduce the misuse of broad-spectrum antibiotics. 
Prior authorization of antimicrobial prescriptions by approved personnel (e.g. medical 
microbiologists, clinical pharmacists) is another way to directly control antimicrobial misuse 
and create learning opportunities for prescribers. However, this may lead to prescribers 
perceiving a loss of autonomy. Antimicrobial prescribing and dispensing policies should be 
7 
 
reviewed regularly and based on updated AMR trends and good clinical practice. A recent 
meta-analysis identified 30 studies on this topic. Notwithstanding that most of the studies 
had a high risk of bias, 26 studies demonstrated that resistance rates for restricted 
antibiotics were significantly decreased across a wide variety of infective agents and that the 
overall effect on mortality was non-significant (Schuts et al., 2016). Subsequently, a review 
of 221 studies confirmed that restriction was independently associated with an increased 
compliance with antibiotic prescribing policies, with no adverse effects on mortality rates 
(Davey et al., 2017).  
2.4 Pathogen identification and antibiotic susceptibility testing 
The preferred antibiotic susceptibility testing method remains phenotypic resistance testing. 
However, this requires a long time to obtain results which inevitably leads to a prolongation 
of empirical therapy using broad-spectrum antimicrobials (Pulido, García-Quintanilla, Martín-
Peña, Cisneros & McConnell, 2013). Novel approaches such as PCR-based techniques, 
mass spectrometry, microarrays, microfluidics, flow cytometry, isothermal microcalorimetry 
(IMC), cell lysis-based approaches and whole-genome sequencing have been developed 
and tested (Pulido, García-Quintanilla, Martín-Peña, Cisneros & McConnell, 2013; van 
Belkum & Dunne, 2013). However, in most cases their sensitivity and specificity compared to 
reference phenotypic methods still requires validation (Pulido, García-Quintanilla, Martín-
Peña, Cisneros & McConnell, 2013). While rapid, accurate and point-of-care pathogen 
identification to shorten the duration of empirical therapy is advocated as an integral part of 
ASPs, it is not yet clear whether the benefits of new technologies over existing diagnostics 
on clinical outcomes and microbial outcomes justifies their huge costs. 
2.5 Digital technology 
The increased use of electronic records and computerized drug ordering systems has 
created opportunities for the electronic surveillance of prescribing practices and the use of 
prescribers’ guidance. Development of electronic systems in liaison with antimicrobial 
stewardship teams can enable point-of-care recommendations at entry level to avoid the 
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misuse of antimicrobials. Programs may also be equipped to identify allergies, incorrect 
dosing and mismatches between the antibiotic and susceptibility profiles. Studies have 
demonstrated a significant positive contribution of electronic systems in the reduction of 
antimicrobial use, length of hospital stay and costs of antimicrobial prescriptions (Yong, 
Buising, Cheng & Thursky, 2010; Filice et al., 2013; Hermsen, VanSchooneveld, Sayles & 
Rupp, 2012). Automated time series analysis tools have also been developed to predict 
susceptibility profiles and evaluate the effect of healthcare interventions on AMR. The 
predictivity of machine learning algorithms on antimicrobial susceptibility has also been 
demonstrated (Oonsivilai et al.,2018; WebResist 2.0). Further long-term, multicenter, 
randomized controlled trials are required to validate effectiveness. Mainstream use of such 
systems is usually hampered by time and financial requirements for their implementation and 
maintenance. 
2.6 Pharmacodynamic Dose Optimization 
Pharmacodynamic dosing strategies are aimed at maintaining the concentration of an 
unbound drug above the minimum inhibitory concentration (MIC) to minimize the emergence 
of resistance. This is achieved through correlation of pharmacodynamic parameters for 
individual antimicrobials with efficacy estimates of their achievable tissue concentrations. A 
recent Cochrane review (Shiu, Wang, Tejani & Wasdell M, 2013)  and multicenter, 
randomized trial (Dulhunty et al., 2015) in critically ill patients comparing continuous 
infusions to standard intermittent dosing did not demonstrate superiority in clinical outcomes, 
although the effect on resistance was not demonstrated. It is therefore important that we 
emphasize that the effect of sub-optimal dosing on AMR at the population level is not yet 
known. 
2.7 Antimicrobial cycling 
Antimicrobial cycling is based on the cyclic substitution of a single antimicrobial or an entire 
class of antibiotics either at the hospital- or unit-level. The rationale behind this technique is 
that temporary antibiotic removal may minimize the emergence of resistance related to long-
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term use of antimicrobials. A 2014 meta-analysis demonstrated a significant reduction in the 
incidence of antibiotic-resistant bacteria after this intervention (reduction of 7·2 per 1000 
patient-days, 95% CI 0·44–14·00; p=0·037). However, this evidence is weak due to the 
inclusion of only a small number of studies with short-term follow up periods, which limits the 
generalizability of the results (Baur et al., 2017; Abel zur Wiesch, Kouyos, Abel, Viechtbauer 
& Bonhoeffer, 2014). Indeed, a recent randomized, cross-over trial showed no reduction of 
AMR in European intensive care units (ICUs) by antibiotic cycling (van Duijn & Bonten, 
2014). Mathematical modelling suggests that either pathogen genotyping or prescribing 
informed by careful surveillance is superior to antibiotic mixing or cycling (Beardmore, Peña-
Miller, Gori, & Iredell, 2017). 
2.8 Post-prescription review and feedback 
Review and feedback are one of the cornerstones of most ASPs. While the length of 
antimicrobial treatment remains at the discretion of the treating clinician, a multidisciplinary 
team will revise the regime after 48–72 hours based on the clinical response and guidelines. 
Feedback is then provided to prescribers. A multicenter study disclosed that 27.3% of 
antibiotic prescribing was “unjustified” and that 66.7% of clinicians accepted 
recommendations to amend or discontinue the course of antibiotics. Additionally, it 
confirmed that a significant reduction in antibiotic usage was observed only in sites with well-
established ASPs (Cosgrove et al., 2012) as also demonstrated by other studies (Yeo et al., 
2012; Newland et al., 2012). This positive effect is likely dependent upon the skills of the 
multidisciplinary team and the availability of state-of-the-art diagnostics. 
2.9 Periodic Antibiotic Monitoring and Supervision (PAMS) 
PAMS is a real-time antibiotic cycling strategy led by a multidisciplinary antimicrobial 
stewardship team (made up of two infectious disease physicians, a pharmacist and an 
infection control nurse). Antibiotic prescribing decisions are supervised to inform periodic 
categorization of antibiotics into “recommended”, “restricted” and “off-supervision” based on 
AMR data. This strategy has shown significant success (Takesue  et al., 2010) which is likely 
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a result of real-time monitoring of AMR incidence (Bal, Kumar & Gould, 2010). Automated 
and iterative time-series analysis can provide infection-syndrome specific guidance on likely 
resistance profiles based on temporal trends in resistance, antibiotic prescribing and their 
relationship (WebResist 2.0).  
2.10 Biomarker-guided diagnostic testing and prescribing 
The reduction in antibiotic prescribing guided by C-reactive protein levels has already been 
demonstrated and incorporated in the National Institute for Health and Care Excellence 
(NICE) guidelines for the diagnosis of pneumonia (Quenot et al., 2013; Little et al., 2013). 
Procalcitonin has been proposed as a potential marker to discriminate between inflammation 
caused by bacterial versus viral infections (Aabenhus, Jensen, Jørgensen, Hróbjartsson & 
Bjerrum, 2014). High strength evidence for procalcitonin-guided discontinuation of antibiotic 
therapy in adult ICU patients with sepsis, as well as, the initiation of antibiotics for lower 
respiratory tract infection exists (de Jong et al., 2016). However, most of the evidence 
emerges from limited studies that have small sample sizes, report modest effect sizes 
between experimental and control groups, and employ heterogenous cutoff values that 
hamper us in reaching any tangible conclusion (Andriolo, Andriolo, Salomão & Atallah, 2017; 
Bouadma et a., 2010). Studies comparing benefit against established stewardship programs 
are lacking. Nonetheless, the marginal benefit of biomarker-guided diagnostics, and point-of-
care testing reliant on lay health workers could be greater in resource-limited countries 
where access to ‘expert assessment’ is less forthcoming. Indeed, a favorable effect on 
antibiotic use and clinical outcomes by point-of-care testing has been shown in Tanzanian 
children with severe infections and in patients attending primary care facilities in Vietnam, 
Thailand and Myanmar (Keitel et al., 2017; Do et al., 2016; Althaus et al., 2018). 
 




3.1 Thresholds in relationships between population use of specific antibiotics and 
AMR 
Antimicrobial exposure measured at population levels reflect a selection pressure that favors 
the emergence of multidrug resistant microorganisms. Most ASPs and empirical evidence 
are based on a ‘use it and lose it’ principle, in which resistance rises linearly with increasing 
antibiotic use in the population. However, for several reasons, including the balance between 
survival advantage and fitness cost of resistance genes, the relationship between 
antimicrobial use and resistance is more frequently non-linear. Practically, complete 
restriction of broad-spectrum antibiotics is not always feasible or desirable despite the 
proven effectiveness of restrictive strategies to reduce AMR rates. For example, over-
restriction leads to increased use of alternative antimicrobials leading to new selection 
pressures or resistance problems (Peterson, 2005). Adverse effects on clinical outcomes are 
also possible, albeit not proven. At a minimum, over-restriction may lead to a strained 
relationship between antimicrobial management teams and clinicians. 
To date, ASPs have lacked rational quantitative targets for the restriction of specific antibiotic 
chemical sub-classes or agents within populations. Where increases in the frequency of 
resistance at the population level are seen only above a critical minimum threshold of 
antibiotic use, the threshold provides a quantitative target for ASP, optimizing the balance 
between access to antibiotics for clinical use, and the control of AMR. A recent study using 
routinely collected data on AMR and population antibiotic use from five European centers, 
has demonstrated how non-linear time-series analysis can identify critical minimum 
thresholds in use-resistance relationships (López-Lozano et al., 2019). Importantly, it 
appears that frequencies of infection with several multidrug resistant pathogens only 
increase where population-wide use of selecting broad-spectrum antibiotics exceeds a 
critical level. Such thresholds will provide a quantitative target for ASPs to balance the use of 
effective antimicrobial therapy and the control of AMR emergence. (López-Lozano et al., 
2019). Study authors suggest thresholds should offer “guidance rather than strict limits”,  but 
policy options should be determined by the confidence-intervals around thresholds. If strict 
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control of resistance is the priority, a conservative approach based on the lower confidence 
limit around the threshold would be suitable; if excessive restriction is a concern, the point 
estimate of threshold would be a suitable target. Thresholds are likely to vary across 
populations and be influenced by host, pathogen, and environmental factors (Lawes et al., 
2015;  Lawes et al., 2017). Therefore, local data should inform guidance tailored to individual 
populations and clinical needs. While the use of thresholds is yet to be evaluated in 
prospective, randomized trials, the current evidence supports its potential to refine ASPs that 
currently call for avoidance of selected broad-spectrum antibiotics. 
3.2 Biocide stewardship 
We wish to draw the reader’s attention to the debate regarding the effect of biocides on the 
emergence and spread of AMR (Webber et al., 2015; Wand, Bock, Bonney & Sutton, 2016). 
This is very important in the context of literature that suggests the superiority of 
chlorhexidine-based universal decolonization in ICUs over more targeted approaches 
(Huang et al., 2013) as well as WHO recommendations (Allegranzi et al., 2016) calling for 
daily skin treatment with chlorhexidine before heart and orthopedic surgery. Research over 
the last decade has not generated definitive data but there is ample evidence suggesting 
that biocide exposure may contribute to the selective pressure driving the rise in AMR 
(Oggioni et al., 2015). Declining susceptibility of Staphylococci, including MRSA, to 
chlorhexidine has been reported worldwide, prompting concerns over the selection of 
multidrug resistant Staphylococci by intensive use of chlorhexidine mediated by the 
resistance gene qacA/B (Otter et al., 2013; Lu et al., 2015; Rondeau et al. 2016). High 
carriage of genes for chlorhexidine and mupirocin resistance, likely related to the intensive 
use of these agents in hospitals, has been associated with an increased prevalence of 
multidrug resistant clones of pathogenic S. epidermidis at the local level and globally (Hijazi 
et al., 2016; Zamudio, Oggioni, Gould, & Hijazi, 2019). Biocide resistance to P. aeruginosa 
has been reported due to mutations in genes, mexR and nfxB, that encode repressors of 
mexAB-oprM and mexCD-oprJ, respectively (Mc Cay, Ocampo-Sosa & Fleming, 2010). 
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Most concerningly, mechanisms of chlorhexidine resistance in Klebsiella pneumoniae were 
also associated with cross-resistance to colistin (Buffet-Bataillon, Tattevin, Maillard, 
Bonnaure-Mallet, & Jolivet-Gougeon, 2016). We recommend that future epidemiological 
studies of hospital-acquired multidrug resistant pathogens include a systematic analysis of 
genes that are associated with a decreased susceptibility to biocides. The findings of this 
should inform the enhancement of decontamination and infection control policies.  
 
4. Challenges of stewardship interventions in resource-rich countries 
In most high-income countries there is little evidence of significant changes in increasing 
secular trends in hospital prescribing of broad-spectrum and last resort antibiotics, such as 
carbapenems and colistin. This is likely a result of the rising rates of AMR itself (Center for 
Disease Dynamics, Economics & Policy, 2015). This AMR spiral has been evidenced in 
vector-autoregression based time-series models (Toth et al., 2018). However, the escalating 
use of broad-spectrum antibiotics is not always justified and partly reflects failures in 
stewardship. 
Economic development is one of the main determinants of the likely capacity to implement 
ASPs. Misuse and abuse of antimicrobials is the primary cause of the rise of AMR in 
developed countries, while in low and middle-income countries (LMICs) AMR is clearly 
compounded by additional socio-political, public health and economic aspects as described 
in section 5 (Laxminarayan, Sridhar, Blaser, Wang & Woolhouse, 2016; Resistance Map. 
Center for Disease Dynamics, Economics & Policy, 2017; Klein et al., 2018). The following 
key challenges associated with the implementation of ASPs in resource-rich countries have 
been identified: 
1. Tailoring of antimicrobial prescribing guidelines to the needs of individual health 
boards or hospitals. 
2. Effective coordination among members of the antimicrobial stewardship teams.  
3. Auditing of adherence to recommendations and identifying areas for improvement. 
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4. Diagnostic uncertainty and fear of poor clinical outcomes leading to unnecessary 
antibiotic prescribing, prolonged use of broad-spectrum antibiotics, use of redundant 
combinations of drugs and failure to de-escalate therapy. 
5. Understanding the role of psychosocial determinants, such as the patients’ 
expectations and the health professionals’ perception of those expectations. 
6. Understanding the role of clinical team dynamics on compliance with ASPs. 
7. Factoring the role of reimbursement systems of national health services and corporate 
interests of the pharmaceutical industry. 
Intensive use of antibiotics contributes to AMR not only when used for definitive treatment, 
but also within prophylactic as well as empirical regimens. 
 
4.1 Risk-benefit of antimicrobial stewardship vs. antimicrobial prophylaxis  
Compliance with evidence-based approaches is advocated to avoid prescribing practices 
that hamper the success of ASPs. Indications for antimicrobial prophylaxis have historically 
included prevention of surgical site infections (SSIs), hospital-acquired and aspiration 
pneumonia, recurrent urinary tract infections, asymptomatic bacteriuria and recurrent cystitis. 
However, the evidence only supports the use of prophylaxis in the prevention of SSIs. 
Antibiotic prophylaxis in the context of hospital-acquired pneumonia and aspiration 
pneumonia has consistently shown no effect on mortality rates (Dragan et al., 2018). On the 
contrary, there is a concern that it may cause microbial imbalances that enhance the risk for 
infection by multidrug resistant organisms. Similarly, a Cochrane study that included five 
clinical trials showed limited evidence to support the benefits of antibiotic prophylaxis in 
recurrent urinary tract infections (Niel-Weise, van den Broek , da Silva & Silva, 2012). A 
recent randomized controlled trial showed a decreased recurrence of urinary tract infections 
in high-risk patients but confirmed an increase in multidrug resistant bacteria in urine and 
fecal samples (Fisher et al., 2018). Equally, a meta-analysis to assess prophylaxis in 
recurrent urinary tract infections among children showed an increased risk of multidrug 
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resistant infections (Selekman et al., 2018). Accordingly, the latest European Association of 
Urology (EAU) guidelines recommend using continuous antibiotic prophylaxis as a last resort 
in cases where alternative strategies have been exhausted (Grabe et al., 2015).  
4.2 Antimicrobial stewardship and empirical prescribing  
Empirical antimicrobial therapy is a critical tool in the early treatment of acute infections as 
well as in the prevention of sepsis and its life-threatening sequelae (Dellinger et al., 2013; 
National Confidential Enquiry into Patient Outcome and Death [NCEPOD], 2015). Empirical 
prescribing guidelines call for broad-spectrum antibiotics in certain scenarios, for example in 
cases of hospital-acquired pneumonia, or combinations of antibiotics for cases of suspected 
sepsis. While advocacy for prompt and effective management of sepsis is justified, the risks 
of overuse of antibiotics arising from sepsis policies are little explored. Moreover, there is 
growing evidence that inappropriate antibiotic treatment leads to worse outcomes after 
empirical therapy, suggesting that survival from sepsis depends on the control of AMR. 
Reconciliation of prompt management of sepsis and the control of AMR requires careful 
clinical algorithms as well as rapid or point-of-care testing that can accurately identify 
between serious infections.  
More simply, it is critical to consider the choice of antibiotic, mode of delivery, an intravenous 
(IV) switch to an oral route and duration of the antibiotic course, the awareness of which 
should extend to all those directly involved in the prevention and treatment of sepsis, 
including emergency physicians, intensivists and surgeons. Infectious diseases doctors, 
medical microbiologists and clinical pharmacists can provide invaluable expertise to inform 
these aspects. A multicenter, prospective, observational, 72-hour snapshot study involving 
67 intensive care units from 32 hospitals in the United States showed alarming findings 
regarding prolonged empirical antibiotic treatment. Out of 660 antibiotics that were 
empirically prescribed to 364 patients, 333 were continued for at least 72 hours in the 
absence of a confirmed infection. Suspected pneumonia accounted for approximately 60% 
of empirical prescribing and the most frequently prescribed antibiotics were vancomycin and 
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piperacillin/tazobactam (Thomas et al, 2015). A UK study, focused on prescribing in primary 
care, also showed that the duration of antibiotic treatments exceeded prescribing guidelines 
(Pouwels et al., 2019).  Further, multiple studies suggest shorter regimens can be equivalent 
in most clinical scenarios. In fact, it has been demonstrated that the duration of antibiotic 
treatment directly relates to AMR indicating that the indiscriminate advice of ‘completing 
course’ is not justified (Teshome, Vouri, Hampton, Kollef,& Micek, 2019). 
Taken together, these findings stress the importance of reassessment and de-escalation of 
antimicrobial therapy based on clinical progress, microbiology culture and susceptibility 
testing. More specifically, it highlights the need for: a) a review of antimicrobial prescriptions 
at 48-72 hours where de-escalation to a narrow-spectrum agent or escalation in line with 
susceptibility results is carried out; b) the use of electronic prescribing systems to remind 
prescribers to review antimicrobial therapy after 48-72 hours and alert them to potential 
mismatches with microbiological culture results (Garnacho-Montero, Escoresca-Ortega & 
Fernández-Delgado, 2015; Masterton, 2011). De-escalation is safe. Observational study 
data suggest that de-escalation may reduce hospital stay and even mortality in pneumonia 
(Paul, Dickstein & Raz-Pasteur, 2016; Ambaras Khan & Aziz, 2018) while a randomized 
controlled trial showed that shortened antibiotic use guided by procalcitonin reduced 
mortality (de Jong et al., 2016). Clearly, organizations should ensure prescribers have ready 
access to the latest evidence-based guidelines. These guidelines must be reviewed 
periodically in response to local antibiograms and in line with the most up to date research.  
 
5. Hurdles to global implementation of antimicrobial stewardship programs 
The control of AMR is a global responsibility and is clearly beyond the scope of a single 
government, department or independent organization, hence the commitment of the WHO in 
tackling AMR. Five factors have been identified as roadblocks to successful implementation 
of ASPs in many countries (Figure 2) (Tiong, Loo & Mai, 2016): i) awareness and political 
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will, ii) finance, iii) coordination, iv) monitoring and v) data and technical capacity. 
Nonetheless, it is acknowledged that national income and adequate financial capacity is a 
pre-requisite to successful implementation of ASPs. Problems associated with suboptimal 
ASP implementation in high-income countries, such as the lack of political support and 
excessive bureaucracy, is compounded in LMICs by the general lack of dedicated funding, 
poor infrastructure and workforce shortages. 
i. Awareness and political will: 
Governments should take ownership of ASP implementation and ensure that it is 
adequately resourced. No substantial progress can be made to reverse AMR unless it 
is made a national priority and the leadership needed to drive ASP actions are taken at 
the government-level. Success of ASPs is also dependent on awareness and 
engagement amongst the general public. 
ii. Finance: 
Sustained investment and funds are required to build systems and support needed for 
the implementation of ASPs. Shortage of public funding is usually a reflection of the 
fact that ASP implementation is not seen as a development priority nor is it embedded 
in government planning or budgeting cycles. Governments should also institute 
strategies to incentivize contributions from the private sector. Joint public-private 
investments should follow a ‘One Health’ approach, extending the principles of ASPs 
beyond human health to include animal, plant and environmental health sectors.  
iii. Coordination across sectors and stakeholders: 
Coordinated actions spanning across human, animal and environmental health 
requires horizontal collaboration across all stakeholders through diverse activities, for 
example knowledge-sharing platforms and multi-stakeholder forums, supported by a 
tiered approach encompassing vertical collaboration from central policymakers to 
frontline health practitioners. Generally, the effectiveness of coordination within sectors 
is partly dependent on the quality of education and training in networking, 
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communication and governance. In resource-limited countries cross-sectorial 
coordination is hampered by the lack of (or poorly resourced) governance policies and 
mechanisms to bridge different sectors. Limited regulation or influence over the private 
sector can also compromise effective cross-sectorial coordination.  
iv. Monitoring and evaluation systems: 
A robust monitoring and evaluation framework is essential in identifying targets, 
tracking longitudinal progress and ensuring accountability. However, this is clearly 
dependent on political stability and adequate funding specifically dedicated to these 
initiatives.  
v. Data and technical capacity: 
Relatively few countries have local and national registries on antimicrobial use and 
AMR that can be used to track the effect of ASPs. Such registries provide essential 
evidence to influence all those involved in NAPs on AMR.  
 
5.1 Socio-politico-economic factors 
A recent report suggests that a range of social, political and economic factors contribute 
directly to AMR globally (Collignon, Beggs, Walsh, Gandra & Laxminarayan, 2018). 
According to this review of data for 103 countries, aspects of “good governance” (lower 
corruption, political stability, rule of law and lower crime), quality of infrastructure (sanitation, 
safe water, internet accessibility, urbanization, and access to electricity) and educational 
attainment were negatively correlated with AMR indices. Interestingly, at a national level, 
‘official’ measures of antibiotic use were not associated with AMR. This surprising finding 
points to the concerning possibility that a large proportion of antibiotics is sourced from 
outside the public sector and even outside formal healthcare. Another study found a positive 
association between rising AMR and access to poor quality antibiotics and falsified products 
(Ozawa et al., 2018). In terms of the effect of management of healthcare systems, higher 
investment in public healthcare services were associated with lower AMR while higher ratios 
19 
 
of private to public health expenditure correlated with higher AMR indices (Collignon, Beggs, 
Walsh, Gandra & Laxminarayan, 2018). Previously, it has been shown that out-of-pocket 
expenditure in the public sector correlated positively with AMR by encouraging patients to 
seek out private care (Alsan et al., 2015) where commercial incentives to over-prescribe are 
enhanced (section 4.3). 
5.2 Commercialization and corporate-driven antimicrobial prescribing 
The risk-adjusted net profit value of antibiotics is three-fold lower compared to an anti-cancer 
drug, seven times lower than neurological drugs and more than ten times lower than 
musculoskeletal drugs (Morel & Mossialos, 2010). Arguably, commercial profits are likely to 
be adversely affected by any initiative aimed at controlling acute infections. This is the main 
reason for the notoriously low interest of the pharmaceutical industry in the development of 
new technologies to control infections. As a result, the onus of combatting AMR has fallen 
entirely on governmental agencies. Collaborative programs between public and private 
sector, by analogy with those established to tackle the HIV/AIDS crisis, are urgently needed 
to foster the development of new treatments and concomitant implementation of ASPs.  
The pharmaceutical industry influences drug prescription practices either directly or 
indirectly. For every newly discovered drug, pharmaceutical firms are given temporary 
monopolistic power through a patent to recover research and development costs. The 
monopoly and restricted availability of a certain antimicrobial can result in under-prescribing, 
which increases infection levels that will in turn increase the demand as well as the monetary 
value of the antimicrobial. Further, profit-driven monopolies will usually neglect longitudinal 
data on the efficacy of the new drug and epidemiology of infections that may compromise 
revenue (Kelly, Zoubiane, Walsh, Ward & Goossens, 2016).  
At the end of the patent period market, competition increases overall market size of the 
product which can drive over-prescribing and impact negatively on efforts to control AMR 
(Herrmann, 2010). This profit-driven approach undermines ASPs at many levels with 
detrimental effects reaching the zenith in market-based healthcare systems. Further 
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research is required to understand the impact of the market on AMR trends. Findings should 
inform the development of policies that factor in the management of corporate profits while 
prioritizing NAPs for AMR. 
5.3 Animal and environmental antimicrobial resistance 
The boost of epidemiological, genetic and mechanistic research relating to AMR in animal 
and environmental health, as well as its integration with AMR research directly relating to 
human health, has been advocated at a global level for quite some time (O'Neill, 2014; One 
Health Basics, 2018). Unfortunately, a systematic observational study showed that only 3% 
of current AMR research funding supports projects relating to environmental AMR (Kelly, 
Zoubiane, Walsh, Ward & Goossens, 2016). Cost-effective environmental surveillance of 
AMR itself is an area in significant need of development. While the number of studies in 
animal health-related research has surged in the last few years, sustained and systematic 
national surveillance of AMR in the animal sector is lacking. This makes the integration of 
animal data with AMR surveillance data in hospitals and the community difficult.  
Based on an FDA report, the total amount of antibiotics sold in the United States for food 
production animals exceeded that sold for human consumption (CDC, 2012). Use of 
antimicrobials as growth promotors for food production animals, including in aquaculture, is 
an area that requires urgent attention as this practice is currently only banned in Europe. 
The intensive use of antibiotics in the farming industry has contributed to the rise of AMR in 
food production animals that, in turn, has spread to humans through the food supply 
(Collignon, Powers, Chiller, Aidara-Kane &  Aarestrup, 2009). A recent meta-analysis 
confirmed that restriction of antibiotic use in food production animals is associated with a 
reduction in AMR in these animals, while evidence of the impact on the general human 
population is more limited and mostly related to direct exposure to food production animals 
(Tang et al., 2017). Future molecular epidemiological studies should also evaluate the long-
term effect on the human resistome (Vanderhaeghen & Dewulf, 2017). In any event, 
restriction measures should be tailored to the national economic landscape in order to 
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minimize the impact on resource-limited farming and food production systems already 
struggling with food security (Littmann, Buyx & Cars, 2015). Restriction should also be 
accompanied by the enhancement of husbandry and housing practices, improved 
biosecurity and infection control measures, including vaccination, all of which will reduce 
unnecessary use of antimicrobials. The key barriers for successful implementation of ASPs 
within veterinary medicine are governance structures, client expectations and market 
competition, cost of microbiological testing and lack of access to education, training and 
resources (Parsonage et al., 2017). While some of the antimicrobial stewardship principles 
which are meant for humans may also be applicable to tackling AMR in the animal sector, it 
is likely that a significant reduction of antimicrobial use in both the animal and environmental 
sectors will ultimately be driven by the development of alternatives to antibiotics. Indeed, the 
development of quality and affordable animal vaccines as well as rapid and affordable point-
of-care tests to guide empirical use of antimicrobials in animals are two priority areas 
(Magouras, Carmo, Stark & Schupbach-Regula, 2017).  
An area that has received very little attention is in the management of disposed 
antimicrobials. Antimicrobials are released into the environment on a massive scale either by 
improper disposal of antibiotics, unregulated dissemination of agricultural waste (Berendsen, 
Wegh, Memelink, Zuidema, & Stolker, 2015) or inadequate treatment of wastewater (Chen, 
Zhang, Ying, Zhou, & Jones, 2015). The cumulative burden of antimicrobials that re-enters 
the ecosystem will likely exert selection pressure on environmental microbial communities, 
and in turn contribute to the rise in AMR. This may be compounded by the release of heavy 
metals and biocides (Frontiers report 2018/19), notwithstanding that the concentrations of 
antimicrobial agents found in surface waters and soil environments are lower than levels 
used in clinical or industrial settings. Stringent measures should be taken to further regulate 
the disposal of farming, industrial and household waste containing antimicrobials. Horizontal 
coordination between the public and policymakers is essential to root out unsafe 
antimicrobial disposal and develop sustainable mitigation technologies. However, 
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implementation of strategies to reduce or remove antibiotics from waste streams are often 
hampered by financial barriers. Further, environmental exposure to multidrug resistant 
pathogens and antibiotics in resource-limited countries is compounded by inadequate 
sanitation perpetuated by socio-political obstacles, e.g. rapidly emerging urban slums which 
are deprived of sanitation to by-pass the provision obligations associated with the ‘formal 
settlement’ status. Ultimately, sanitation initiatives to control AMR should be integrated with 
the wider WASH agenda. 
 
6. Strategies to increase global ASP implementation 
6.1 Tiered national-level model 
To date most implementation strategies have been directed at high-income countries that 
already have robust regulatory frameworks and well-functioning healthcare systems. As a 
matter of priority, the focus of ASPs should be broadened to include LMICs that are hot 
spots for AMR. A non-exhaustive list of challenges associated with AMR control in LMICs 
include poor water quality and sanitation, overcrowded housing, poor infection control 
practices, under-resourced healthcare systems, lack of prescribing policies and guidelines, 
suboptimal infectious diseases and clinical pharmacy training programs, and weak data 
management systems. “Tiered national-level antibiotic stewardship activities” laid down by 
CDC may be a pragmatic tool to guide the introduction of ASPs in LMICs (CDC. The Core 
Elements of Human Antibiotic Stewardship Programs in Resource -Limited Settings: 
National and Hospital Levels, 2018). According to this model, ASP activities are tiered into 
A) basic: not requiring dedicated resources and primarily reliant on existing personnel and 
technical expertise, B) intermediate: requiring dedicated staff for ASP planning and 
implementation as well as some level of estate investment, C) advanced: requiring the 
establishment of a formal and holistic program with trained staff and dedicated infrastructure 
as discussed in previous sections. 
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Basic: A multi-sectorial decision-making ASP body sets a NAP on AMR aligned with the 
stewardship goals of the WHO Global Action Plan but tailored to local needs and availability 
of resources. Equally, at the operational level, representatives from a range of relevant 
sectors - ministries, civil society and healthcare - are responsible for implementing the ASP 
activities within the NAP in a coordinated fashion. ASPs should include public engagement 
initiatives to raise awareness of the potentially catastrophic effects of the misuse of 
antibiotics.  
Intermediate: In additional to the above, this model should include an institution of registries 
on epidemiological data on community- and hospital-acquired infections to inform the 
development of evidence-based treatment guidelines. Rural and primary healthcare centers 
should have easy access to appropriate formularies for ACCESS antibiotics, as defined by 
the WHO essential medicine list, while RESERVE antibiotics may be limited to hospitals. 
Investment in enhancing the efficiency of diagnostic testing should also be integral at this tier 
(WHO updates Essential Medicines List with new advice on use of antibiotics, and adds 
medicines for hepatitis C, HIV, tuberculosis and cancer, 2017). 
For both models we strongly advocate that public sector initiatives are associated with 
stringent regulations of the private and informal sectors. 
6.2 Mainstreaming and regional cooperation 
Mainstreaming initiatives are based on optimizing the uptake of existing ASPs and 
enhancing the programs themselves rather than de novo initiatives. In a mainstreamed 
approach, the ASP should be anchored to existing strategic plans concerning human, animal 
and environmental health. Cross-sectorial coordination within mainstreaming initiatives is 
facilitated through an initial focus on priority sectors and the gradual incorporation of 
additional sectors horizontally and vertically.  
The first step in mainstreaming is to map national activities and identify potential entry 
points. To ensure full participation, transparency and legitimacy, such mapping should cover 
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both governmental and non-government activities. Decision tools, tailored to the disease 
burden and socioeconomic status, can then be used to identify the activities that are easiest 
to scale up, most cost-effective and have the greatest impact on AMR and infection control 
outcomes.  
Analogous to climate change agreements, international cooperation is a need of the hour, 
particularly in countries divided politically but united by common cultural, social and 
economic backgrounds. Examples include “the European One Health Action Plan against 
AMR” and “the ASEAN regional strategy on AMR”. Increased regional cooperation helps to 
tackle the cross-border threat of AMR, ensuring that inaction in one area does not 
undermine progress in others. It strengthens solidarity and opens the door for knowledge 
exchange and learning. Principles of regional cooperation include: 
a) Common funding mechanisms to mobilize resources within regions. 
b) Joint procurement programs to help small or resource-poor countries to access a 
sustainable (and cheaper) supply of good-quality antimicrobials at reduced 
transaction costs. 
c) Shared data platforms to collect and analyze antibiotic use and AMR data in 
human and animal populations. 
d) Shared infrastructure e.g. regional laboratory facilities, to support cross-border 
AMR monitoring. 
e) Shared regulatory and legal frameworks to coordinate and implement cross-
regional legislation and guidelines. 
f) Joint research networks and training programs. 
g) Joint awareness campaigns to increase the understanding of AMR among 
stakeholders throughout a region. Multi-stakeholder networks and forums for 
knowledge exchange can help countries learn from each other, share ideas, 
build consensus, compare progress and accelerate national work. 
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The implementation of mainstreaming and regional cooperation is clearly dependent on 
strong political commitment and adequate funding to the following areas: i) surveillance of 
AMR; ii) surveillance of antimicrobial use; iii) development and implementation of national 
infection control standard treatment guidelines; iv) operational research on antimicrobial 
usage, environmental surveillance and antibiotic susceptibility testing methodology; and v) 
antimicrobial stewardship education of healthcare workers and awareness amongst the 
general public. 
6.3 Behavioral interventions 
Alongside strategies tackling social, political and economic barriers, as described above, it 
has been suggested that interventions aimed at modifying prescribing behavior at the 
individual level may have a significant impact on AMR control. However, it is not clear which 
behavioral technique can effectively improve prescribers’ attitudes towards antibiotic 
prescribing. A Cochrane review that included 221 studies demonstrated, with high-certainty 
evidence, that both enablement and restriction were independently associated with 
increased compliance with antibiotic prescribing guidelines (Davey et al., 2017). It was also 
shown that such interventions reduced the duration of antibiotic treatment and length of 
hospital stay. The same report showed that feedback strategies were equally effective, but 
the number of relevant studies was limited. Nonetheless, the authors raised concerns that 
feedback and restriction interventions can lead to delays in treatment and a breakdown of 
trust between infection specialists and clinical teams. More research studies are needed to 
assess the unwanted effects of restrictive strategies. Studies exploring action planning and 
goal setting were too few to infer any conclusions with regards to the benefit of these 
behavioral change techniques.  
Future research should further establish which behavioral change strategy will likely facilitate 
ASP implementation with consideration to additional challenges faced by resource-limited 
countries (Davey et al., 2017; Rzewuska et al., 2019).  
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6.4 Public awareness 
Implementation of ASPs should transcend beyond healthcare professionals to involve active 
participation of the general public. Systematic reviews have demonstrated that joint 
involvement of physicians and patients facilitates the reduction of unnecessary antibiotic use 
(Arnold & Straus,2005; Ranji, Steinman, Shojania & Gonzales, 2008). Educational 
campaigns on the appropriate use of antimicrobials using written material and mass media 
have been shown to bring a positive behavioral change amongst patients and the general 
public (C. Lee, J. Lee, Kang, Jeong & S. Lee, 2015). The individual impact of various public 
campaigns in Europe between 1997 and 2007 has been estimated to be equivalent to a 6.5– 
28.3% drop in the mean level of overall antibiotic use (Filippini, Ortiz & Masiero, 2013), 
although arguably it is not possible to demonstrate its independent effect from other 
components of ASPs. The potential benefit of embedding antimicrobial stewardship 
principles in school educational programs has been reported in relatively small studies (C. 
Lee, J. Lee, Kang, Jeong, & S. Lee, 2015), but the long-term effect of these initiatives is yet 
to be evaluated. Clearly AMR campaigning should go hand in hand with awareness of key 
basic infection control practices (Curtis et al., 2011). Unfortunately, recent reports suggest 
limited AMR awareness amongst the general public. For example, a lack of awareness that 
antibiotics fail to relieve viral infections and that prescribed medications should not be shared 
or hoarded, have been reported (Jamhour, El-Kheir, Salameh, Hanna, & Mansour, 2017). 
While this data confirms the importance of public campaigning, we wish to stress that 
increased awareness of AMR does not necessarily translate into behavioral changes that will 
facilitate the implementation of ASPs. 
 
7. Conclusion  
Unfettered use of antimicrobials in humans, animals, plants and the environment has led to 
an increase in global AMR rates. Antimicrobial stewardship could potentially contribute to the 
reversal of current AMR trends. ASPs should be tailored to the socioeconomic status of each 
27 
 
country, and efforts to identify social, political and economic factors contributing to AMR 
should continue. ASPs must be implemented within both hospital and community settings 
and be driven by cross-sectorial coordination horizontally and vertically. There is currently no 
definitive evidence to demonstrate the superiority of a single antimicrobial stewardship 
strategy. In the interim, monitoring of the adherence to evidence-based clinical guidelines 
should be practiced. We also strongly advocate that ASP models are informed by population 
level thresholds of antibiotic use. The development of point-of-care diagnostics and rapid 
antimicrobial susceptibility testing to minimize empirical prescribing of broad-spectrum 
antimicrobials should be a priority. Consideration must be given to broadening the scope of 
current ASPs to include biocide use in hospitals. Global implementation and success of 
ASPs rests on five pillars - governmental commitment, multi-sectorial collaboration, AMR 
surveillance, funding and monitoring-feedback systems to track progress. The tiered 
national-level model as well as mainstreaming and regional cooperation may facilitate the 
global implementation of ASPs, while behavioral interventions to modify prescribing trends 
also merit attention. Research relating to AMR in animal and environmental health as well as 
its integration with human data requires a significant boost in order to pursue the ‘One 
Health’ approach. Enhanced investment by both the public and private sectors in new 
technologies to control infections and AMR should be a priority. Joint public-private sector 






Expert Opinion  
AMR is a global health threat that spans the entire socioeconomic spectrum and remains 
one of the top ten WHO priorities. To tackle this complex issue, all contributing factors 
should ideally be addressed within NAPs for AMR, resources permitting. ASPs can 
rationalize the use of antibiotics and make a significant contribution to tackling AMR but they 
should be tailored to the needs and financial capacity of individual countries. On the other 
hand, the onus of identifying the factors that contribute to AMR rates and customizing the 
general principles of ASPs should fall on individual countries or preferably regions in the 
spirit of regional cooperation. The availability of resources and the strength of infrastructure 
are two main determinants that should shape ASPs. Ultimately, the successful 
implementation of ASPs depends on the selection of an appropriate strategy. 
Notwithstanding that high-quality evidence to demonstrate the superiority of a single 
antimicrobial stewardship strategy over others is lacking, any ASPs should include, as a 
bare minimum, the evaluation of adherence to evidence-based clinical guidelines for 
antimicrobial use and the use of feedback to enhance compliance. We strongly advocate 
ASP models informed by population level thresholds of antibiotic use over arbitrary total 
restrictions of broad-spectrum antibiotics. Importantly, the impact of ASPs should be 
monitored at timely intervals and their content revised based on the current epidemiology of 
community- and hospital-acquired infections and AMR data. 
The development of point-of-care diagnostic and rapid antimicrobial susceptibility testing to 
minimize empirical prescribing of broad-spectrum antimicrobials should be a priority. 
Consideration must be given to broadening the scope of current ASPs to include biocide use 
in hospitals. While more research is required to fully assess the impact of biocide use on 
AMR trends, based on current evidence we suggest that indiscriminate use of biocides 
should be avoided.  
AMR is clearly a multi-sectorial problem, hence the lack of cross-sectorial coordination 
(vertical and horizontal) and accountability are two major obstacles to the achievement of the 
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desired ASP outcomes. Increased clarity and transparency of the roles of representatives 
from different sectors will partly tackle these two issues. Global implementation and success 
of ASPs rests on five pillars - governmental commitment, multi-sectorial collaboration, AMR 
surveillance, funding and continuous monitoring. The tiered national-level model as well as 
mainstreaming and regional cooperation may facilitate global implementation of ASPs - in 
particular ASP adoption and implementation in resource-limited countries.  
The remit of ASPs should span across humans, animals, plants and the environment in 
perusal of the ‘One Health’ approach advocated by all AMR NAPs. However, more research 
is required to enhance our understanding of AMR in all these areas, specifically as to how 
they interact with one another. In the interim, policies to minimize unnecessary or subclinical 
doses of antimicrobials in animals and plants should be enforced. 
Enhanced investment in the discovery of new antibiotics and other cost-effective alternatives 
by both the public and private sector should be a priority. We suggest that access to 
antimicrobials should be driven by public health evidence and should not be influenced by 
the commercial interests of the pharmaceutical industry.  
Behavioral interventions to modify prescribing trends are a promising area but more work is 
required to identify specific techniques that will likely contribute to changing antimicrobial 
prescribing behavior. The focus on patient attitude is also critical, thus public engagement 
initiatives to promote responsible use of antibiotics as well as fundamental infection control 
and sanitation practices are important. While impactful changes in antimicrobial prescribing 
practices will clearly require sustained engagement and commitment of the public and 
healthcare professionals, we warn against over-estimating the potential benefit of behavioral 
interventions. We note a general misalignment between personal behavior and commitment 
to societal impact and, on this basis, strongly advocate population level stewardship 
interventions in association with an investment in structural factors that will aid the 
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